<DOC>
	<DOCNO>NCT00632489</DOCNO>
	<brief_summary>This single center Phase I dose escalation trial evaluate safety , tolerability efficacy LBH589 combine capecitabine lapatinib three part . Part 1 determine maximum tolerated dos ( MTD ) LBH589 combine capecitabine . Parts 2 3 limited locally recurrent metastatic breast cancer patient , ICH 3+ overexpression FISH amplification document locally . Part 2 evaluate safety MTD LBH589 determine Part 1 pair lapatinib 1000 mg mouth ( PO ) daily . Parts 2 3 limited locally recurrent metastatic breast cancer patient , ICH 3+ overexpression FISH amplification document locally . Part 3 evaluate tolerability effectiveness triplet combination , LBH589 , capecitabine lapatinib breast cancer patient .</brief_summary>
	<brief_title>LBH589 Combination With Capecitabine Plus/Minus ( ± ) Lapatinib Breast Cancer Patients</brief_title>
	<detailed_description>LBH589 evaluate administered twice weekly follow possible dose level : 20 mg , 30 mg , 45 mg , 60 mg. Capecitabine pair LBH589 range dose 825 mg/m2 1250 mg/m2 orally BID 14 every 21 day . Treatment cycle 21 day length . Once determined safe , 10 additional patient treat determined MTD ass safety . The second portion study ass QTc prolongation LBH589 lapatinib combination . A subset 6 patient treat LBH589 one dose MTD determine Part I . If tolerate , 6 additional patient receive LBH589 MTD establish Part I lapatinib ( capecitabine administer subset patient ) . If clinically significant finding LBH589 lapatinib subset , study advance third portion combine three drug LBH589 , capecitabine , lapatinib . The triple combination initially administer lapatinib 1000 mg orally daily LBH589 capecitabine one dose level establish MTD . If tolerate , LBH589 capecitabine dos escalate MTD . Toxicity assessments ongoing disease assessment repeat every 2 treatment cycle . If dose level combination explore , total 45-55 patient require accommodate additional patient enrol QTc subset establish recommended phase II dose combination regimen .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>1 . Histologically document metastatic locally unresectable , incurable malignancy capecitabine clinically appropriate . 2 . Male female patient age ≥ 18 year old . 3 . Maximum 3 prior regimen metastatic setting allow may include targeted agent , immunotherapy chemotherapy . 4 . Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . 5 . Eastern Cooperative Oncology Group performance status ( ECOG PS ) 0 1 . 6 . Baseline MUGA ECHO must demonstrate LVEF &gt; low limit institutional normal . 7 . Laboratory value follow : ANC &gt; 1500/μL Hgb &gt; 9 g/dL Platelets &gt; 100,000/uL Bilirubin &lt; 1.5 mg/dL AST/SGOT &lt; 2.5 x ULN &lt; 5.0 x ULN ALT/SGPT patient liver metastasis Creatinine &lt; 1.5 mg/dL calculate creatinine clearance &gt; 50 ml/min Albumin &gt; 3 g/dL Potassium &gt; low limit normal ( LLN ) Phosphorous &gt; LLN Calcium &gt; LLN Magnesium &gt; LLN 8 . Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior start treatment must commit begin two acceptable method birth control , one highly effective method birth control one additional effective method time start treatment . 9 . Life expectancy &gt; 12 week . 10 . Accessible treatment followup . 11 . All patient must able understand nature study give write informed consent prior study entry . Additional Breast Cancer Patient Subset ( Part 2 Part 3 ) 1 . Incurable carcinoma breast , measurable locally recurrent metastatic disease . 2 . ICH 3+ overexpression FISH amplification document local laboratory primary metastatic tumor tissue . 3 . Prior treatment anthracycline , taxane , trastuzumab candidate treatment . Patient may receive drug combination sequence treatment locally advance metastatic disease and/or adjuvant therapy . 1 . Prior treatment HDAC inhibitor current treatment valproic acid . 2 . Previous treatment capecitabine . 3 . Impaired cardiac function include follow : Screening ECG QTc &gt; 450 msec . Congenital long QT syndrome . History sustain ventricular tachycardia . Any history ventricular fibrillation torsades de pointes . Bradycardia define heart rate &lt; 50 beat per minute . Patients pacemaker heart rate &gt; 50 beat per minute eligible . Myocardial infarction unstable angina within 6 month study entry . Congestive heart failure ( NY Heart Association class III IV ) . Right bundle branch block leave anterior hemiblock ( bifascicular block ) . Atrial fibrillation flutter . Ongoing therapy antiarrhythmic medication associate QTc prolongation . 4 . Uncorrected hypokalemia hypomagnesaemia . 5 . Uncontrolled hypertension ( systolic blood pressure [ BP ] 180 diastolic BP &gt; 100 mm Hg ) uncontrolled cardiac arrhythmia . 6 . Active CNS disease , include meningeal metastasis . 7 . Known diagnosis human immunodeficiency virus ( HIV ) infection . 8 . Unresolved diarrhea &gt; CTCAE grade 1 . 9 . Concomitant requirement medication classify CYP3A4 inducer inhibitor . 10 . Patients history allergic reaction attribute compound similar chemical biologic composition lapatinib . 11 . Patients know hypersensitivity 5fluorouracil chemotherapy , investigational drug therapy , major surgery &lt; 4 week prior start study drug patient recover side effect previous therapy . 12 . Patient &lt; 5 year free another primary malignancy except primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . 13 . Concomitant use anticancer therapy radiation therapy . 14 . Pregnant breast feed female reproductive potential use two effective method birth control . 15 . Male patient whose sexual partner woman childbearing potential use effective birth control . 16 . Patients gastrointestinal ( GI ) tract disease , cause inability take oral medication , malabsorption syndrome , requirement intravenous ( IV ) alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease , ulcerative colitis ) . 17 . Other concurrent severe , uncontrolled infection intercurrent illness , include limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 18 . Patients take medication list `` Prohibited Medications '' capecitabine lapatinib . 19 . Patients uncontrolled coagulopathy ( PT and/or PTT &gt; 1.2 x ULN ; patient must also stable dose anticoagulant define medical indication ) . 20 . Abnormal thyroid function ( TSH free T4 ) detect screen . Patients known hypothyroidism stable thyroid replacement eligible . Additional Breast Cancer Patient Subset ( Part 2 Part 3 ) 1 . Prior treatment lapatinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Refractory Malignancy</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>LBH589</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Lapatinib</keyword>
</DOC>